World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
143
Citations
71666
World Ranking
1518
National Ranking
881

Timothy F. Cloughesy publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Timothy F. Cloughesy sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 724 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Timothy F. Cloughesy D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Timothy F. Cloughesy sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 143 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Timothy F. Cloughesy is affiliated with the University of California, Los Angeles in the United States. Their research primarily focuses on medical fields with a strong emphasis on glioma diagnosis and treatment, radiomics and machine learning in medical imaging, and various cancer-related areas.

Cloughesy's work covers several main fields of study, including Medicine and Biochemistry, Genetics and Molecular Biology. Their subfields of study encompass Genetics, Radiology, Nuclear Medicine and Imaging, Cancer Research, Molecular Biology, and Pulmonary and Respiratory Medicine.

The main topics of their research include:

  • Glioma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • MRI in cancer diagnosis
  • Cancer, Hypoxia, and Metabolism
  • Medical Imaging Techniques and Applications
  • Cancer Genomics and Diagnostics
  • Advanced MRI Techniques and Applications

Among recent publications attributed to their research domain are:

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, 2020, Neuro-Oncology
  • Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma, 2023, New England Journal of Medicine
  • Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial, 2022, Neuro-Oncology
  • RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults, 2023, Journal of Clinical Oncology
  • Federated learning enables big data for rare cancer boundary detection, 2022, Nature Communications

Frequent publication venues for Cloughesy include:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Neuro-Oncology Advances
  • Journal of Neuro-Oncology
  • Nature Communications

The scientist has collaborated frequently with several co-authors such as:

  • Benjamin M. Ellingson
  • Patrick Y. Wen
  • Phioanh L. Nghiemphu
  • Linda M. Liau
  • Catalina Raymond

Best Publications

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen

  • Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

    Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson

  • Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

    Ingo K. Mellinghoff;Maria Y. Wang;Igor Vivanco;Daphne A. Haas-Kogan

  • Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

    Rameen Beroukhim;Gad Getz;Leia Nghiemphu;Jordi Barretina

  • High-throughput oncogene mutation profiling in human cancer

    Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler

  • Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

    Timothy F. Cloughesy;Aaron Y. Mochizuki;Joey R. Orpilla;Willy Hugo

  • Gene Expression Profiling of Gliomas Strongly Predicts Survival

    William A. Freije;F. Edmundo Castro-Vargas;Zixing Fang;Steve Horvath

  • Standards of care for treatment of recurrent glioblastoma—are we there yet?

    Michael Weller;Timothy Cloughesy;James R. Perry;Wolfgang Wick

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

    S. Horvath;B. Zhang;M. Carlson;K. V. Lu

  • Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

    Benjamin M. Ellingson;Martin Bendszus;Martin Bendszus;Jerrold Boxerman;Daniel Barboriak

  • Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

    Tim F Cloughesy;Koji Yoshimoto;Phioanh Leia Nghiemphu;Kevin Brown

  • Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

    Linda M. Liau;Robert M. Prins;Sylvia M. Kiertscher;Sylvia K. Odesa

  • Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.

    David A. Nathanson;Beatrice Gini;Jack Mottahedeh;Koppany Visnyei

  • Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

    David A. Reardon;Karen L. Fink;Tom Mikkelsen;Timothy F. Cloughesy

  • Glioblastoma: From Molecular Pathology to Targeted Treatment

    Timothy F. Cloughesy;Webster K. Cavenee;Paul S. Mischel

  • Analysis of the Phosphatidylinositol 3′-Kinase Signaling Pathway in Glioblastoma Patients in Vivo

    Gheeyoung Choe;Steve Horvath;Timothy F. Cloughesy;Katherine Crosby

  • Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

    Albert Lai;Anh Tran;Phioanh L. Nghiemphu;Whitney B. Pope

  • Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG

    Wei Chen;Timothy Cloughesy;Nirav Kamdar;Nagichettiar Satyamurthy

Frequent Co-Authors

Albert Lai
Albert Lai University of Washington
Linda M. Liau
Linda M. Liau University of California, Los Angeles
Patrick Y. Wen
Patrick Y. Wen Harvard University
Paul S. Mischel
Paul S. Mischel Stanford University
David A. Reardon
David A. Reardon Harvard University
Michael D. Prados
Michael D. Prados University of California, San Francisco
Ingo K. Mellinghoff
Ingo K. Mellinghoff Memorial Sloan Kettering Cancer Center
Susan M. Chang
Susan M. Chang University of California, San Francisco
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Lisa M. DeAngelis
Lisa M. DeAngelis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens doors to many alternative healthcare fields and study paths beyond traditional medical school. Prospective students looking for flexibility may consider online options, such as online adn programs for non nurses. These programs are designed for those without prior nursing experience and can be a quicker route into nursing roles.

Not all roles in healthcare require direct patient care or extensive medical training. Administrative positions are in high demand, and accredited programs in healthcare administration degree can be earned entirely online, often in an accelerated timeframe. For those interested in medical data and office support roles, consider medical billing and coding schools that accept financial aid, making entry into the field financially accessible for many.

It's also important to understand testing requirements when applying for healthcare programs. Many students ask, do you have to take a teas test for lpn? Some nursing schools no longer require standardized exams like the TEAS or HESI, offering a streamlined application process for aspiring nurses.

Best Scientists Citing Timothy F. Cloughesy

Trending Scientists

Recently Published Articles